Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.
about
Interventions for renal vasculitis in adultsPauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated VasculitisPathophysiological Relationship between Infections and Systemic VasculitisCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Pathogenesis of ANCA-associated vasculitisA case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure.Pathogenesis of ANCA-associated vasculitis.MRSA induced pulmonary-renal syndrome.Treatment of ANCA-associated vasculitis.Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?Management of Small Vessel Vasculitides.Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.Vasculitis for the internist: focus on ANCA-associated vasculitis.Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis.Wegener's granulomatosis in a middle-aged woman presenting with dyspnea, rash, hemoptysis and recurrent eye complaints: a case reportMaintenance of clinical remission in ANCA-associated vasculitis.Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisGranulomatosis with Polyangiitis in Children
P2860
Q24187038-2475DA47-2076-498D-A8BF-7460DE3B988BQ26774594-98021051-C3DB-4EA6-BA6D-26416869D5E9Q26799915-DAE32E60-3B18-46CF-83E2-5269C4D292F3Q27025692-262E0605-7665-41DB-B179-2E2D13E171AFQ28390438-B58B27F6-8DB4-410D-BE17-B02D743F59F4Q30317533-5CB6FB48-22EE-4DD5-86A0-1C3616B98089Q33556028-733CF7EA-78A6-4BD4-85A7-77C5CA74518FQ34296337-0597AEE4-2C7B-408A-83E4-D43A4932332BQ37447394-9C821481-EE6F-4DD1-84B3-AB9BFC962512Q38159916-6876B21A-B7C2-4B96-B72D-4C6836E95446Q38794907-46326105-85B9-4F21-B078-D4CB100CB069Q38818682-77239350-8D80-4526-8741-E900E8659B28Q39072021-4C36501E-1365-47A8-B29E-6257B9613DC0Q39379384-83CB48B8-2567-4E2D-90D2-66141475E21BQ41126772-2C408B40-D74B-4787-9D35-685816BF41C7Q41387855-3538B4BF-5D3B-4FB3-B94A-D29C80474DD5Q45752892-F5068787-BAC8-49DC-BBF9-6279F9D1BD42Q59160663-1FDD2124-6728-41B1-961B-B9785F6F0016Q59160666-1723E915-D543-4287-925E-7072C2DAB309
P2860
Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@ast
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@en
type
label
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@ast
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@en
prefLabel
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@ast
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@en
P2093
P2860
P1476
Co-trimoxazole and prevention ...... is with pulmonary involvement.
@en
P2093
P2860
P2888
P304
P356
10.1186/2047-783X-14-S4-265
P407
P478
14 Suppl 4
P577
2009-12-01T00:00:00Z
P5875
P6179
1027194610